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Diabetes mellitus is associated with decreased NO bioavailability in the myocardium. Ginsenoside Rb1 has been shown to confer
cardioprotection against ischemia reperfusion injury. The aim of this study was to investigate whether Ginsenoside Rb1 exerts
cardioprotective eﬀects during myocardial ischemia-reperfusion in diabetic rats and whether this eﬀect is related to increase the
production of NO via enhancing eNOS expression in the myocardium. The myocardial I/R injury were induced by occluding the
left anterior descending artery for 30min followed by 120min reperfusion. An eNOS inhibitor L-NAME or Rb1 were respectively
administered 25min or 10min before inducing ischemia. Ginsenoside Rb1 preconditioning reduced myocardial infarct size when
compared with I/R group. Ginsenoside Rb1 induced myocardial protection was accompanied with increased eNOS expression
and NO concentration and reduced plasma CK and LDH (P<0.05). Moreover, the myocardial oxidative stress and tissue
histological damage was attenuated by Ginsenoside Rb1 (P<0.05). L-NAME abolished the protective eﬀects of Ginsenoside
Rb1. It is concluded that Ginsenoside Rb1 protects against myocardium ischemia/reperfusion injury in diabetic rat by enhancing
the expression of eNOS and increasing the content of NO as well as inhibiting oxidative stress.
1.Introduction
Diabetes mellitus has long been identiﬁed as the leading
cause of the development of ischemic heart disease within
the diabetic population [1]. Many epidemiological ﬁndings
unanimously support the fact that cardiovascular diseases
(CVD) are the primary mortality factor among diabetic
patients [2]. The diabetic state is associated with increased
oxidative stress, and the hyperglycemia further stimulates
the production of advanced glycosylated end products,
which increase microvascular permeability. Moreover, the
abnormal lipid metabolism increases oxidized low-density
lipoprotein (ox-LDL) formation, resulting in oxidative stress
which exacerbates myocardial and vascular endothelial cell
insult due to myocardial ischemia/reperfusion injury. Hearts
from diabetic subjects are less resistant to ischemic insults
[3, 4]. We have recently demonstrated that postischemic
myocardial infarct sizes were signiﬁcantly larger in diabetic
rats 8 weeks after STZ-injection as compared to non-diabetic
controls [5], and we have found that Rb1 can confer cardio-
protection in diabetic rats. However, the mechanism by
which Rb1 confers cardioprotection in diabetes has not
been explored. Therefore, in the current study, we explored
whether or not enhancing nitric oxide bioavailability plays
a critical role in Rb1-mediated cardioprotection in diabetic
subjects.
Nitricoxide(NO)isafundamentalendothelium-derived
relaxingfactor(EDRF),whichatphysiologicalconcentration
possesses vasodilatory properties inhibits leukocyte and
platelet adherence, suppresses smooth muscle cell hyperpla-
sia [6], and is also beneﬁcial in limiting myocardial ischemia/
reperfusion (MI/R) injury. Numerous studies have already
demonstrated the cardioprotective eﬀects of NO during
ischemia/reperfusion events [7, 8]. However, in patients
with long-standing diabetes, the availability of NO decreases
progressively [9]; in addition, eNOS expression is reduced
as well as mediators for the synthesis of NO. Hence, such
situations aggravate vascular endothelial dysfunction and2 Journal of Biomedicine and Biotechnology
atherosclerosis in diabetes [10, 11]. In animal studies, it
has been found that eNOS provides protection to some
extent against I/R injury to extracorporeal hearts [12], and
bioavailability of NO and availability of eNOS decrease I/R
injuryandpromotereperfusionofmyocardialinfarctionand
after-heart failure in left ventricular function recovery [13].
Ginsenoside Rb1 is the main bioactive component of
GinsengandShenfuinjection.Ithasvariousbeneﬁcialeﬀects
on the cardiovascular system, such as scavenging free rad-
icals, blocking calcium overinﬂux into neurons, inhibiting
Na+ channel activities, improving energy metabolism, and
preserving the structural integrity of the neurons, among
many others [14]. Recent studies have demonstrated that
Ginsenoside Rb1 has protective eﬀects against myocardial
ischemic injury in nondiabetic animals [15] and the molec-
ular mechanism of this beneﬁcial eﬀect is still unidentiﬁed.
The present study aims to determine whether Ginseno-
side Rb1 preconditioning can protect against I/R injury in
diabetic rats by enhancing the expression of eNOS and
increasing the content of NO as well as inhibiting oxidative
stress.
2.MaterialsandMethods
2.1. Experimental Animals. The experimental procedures
and protocols used in this research work were approved by
the Animal Use Committee of Wuhan University. Healthy
male adult Sprague-Dawley (SD) rats (weighing 220∼280g),
procured from the Experimental Animal Centre of Wuhan
University. After one week of adaption period, they were
kept fasting for 12hr and injected with streptozotocin
(STZ; Sigma, USA; pH 4.5) intraperitoneally at a dosage
of 65mg/kg. Five days after STZ injection, the rats were
kept fasting for 5hr, and the blood samples from the tails
were collected and fasting blood sugar was measured using
SureStrep glucometer (Johnson & Johnson Company). Rats
with blood glucose level ≥16.7mmol/L (300mg/L) were
considered diabetic models [16].
2.2. Myocardial Ischemia: Reperfusion Model. After a 12
hour period of fasting, the animals were anesthetized with
3% pentobarbital sodium injection (50mg/kg) administered
intraperitoneally and then ﬁxed on the operating table for
surgical procedures. ECG electrodes were placed subcuta-
neously in both front limbs and left back limb and lead II
was continuously monitored. A 14-gauge angiocatheter was
insertedintothetracheathroughamidlineneckincisionand
thenconnectedtoavolume-controlledventilator(DW-2000,
Jiapeng Keji, Shanghai, China). The left femoral vein was
catheterized for intravenous administration of drugs. The
physiological saline or drugs (Ginsenoside Rb1, L-NAME)
was slowly administered through the femoral catheter.
Heparin (500U/kg) was administered intravenous and the
right carotid artery was catheterized for the continuous
monitoring of mean arterial pressure (MAP) and for blood
sampling. The electrocardiogram and blood pressure signal
was displayed on an M3 monitor (Siemens, Germany).
A left thoracotomy in the fourth intercostal space was
performed and the pericardium was opened. A 6–0 silk
suture was passed with a tapered needle under the left
anterior descending coronary artery, 2mm from the tip of
the leftauricle.The ends ofthe suturewerethreaded through
a piece of plastic tubing, forming a snare that occluded the
artery when tightened and clamped. The coronary artery
was occluded for 30min and then allowed reperfusion (by
releasing the clamp) for 2hr.
2.3. Experimental Protocol. The diabetic rats were randomly
assignedtoﬁvegroups,andeachgroup8rats:group1,sham-
operated rats (Sham); group 2, ischemia/reperfusion group
(30min of myocardial ischemia and 120min of reperfusion,
I/R); group 3, Ginsenoside Rb1 preconditioning group,
Ginsenoside Rb1 40mg/kg was administered intravenously
10minbeforecoronaryischemiaandreperfusion(Rb1)[14];
group 4, L-NAME + I/R group, L-NAME was given at a
dose of 10mg/kg 25min before ischemia (L-NAME) [17];
group 5, L-NAME + Ginsenoside Rb1-treated group (L-
NAME + Rb1). In the second set of experiments, seven
similar experimental groups of rats (n = 4i ne a c hg r o u p )
were subjected to the same experimental procedures. At
the end of reperfusion, the animals were sacriﬁced by an
intravenous injection of 10% potassium chloride solution,
and myocardial samples were collected from ischemic left
ventricle regions for protein analysis. All animals survived
after ischemia reperfusion until being terminated at the
completion of the experiment. The samples were frozen in
liquid nitrogen, and stored at −80◦C for later analysis.
2.4. Determination of the Area at Risk and Infarct Size. At
the end of the 2hr of reperfusion, the rats were given
heparin (1U/g, intraperitoneally). The coronary artery was
reoccluded, and 1mL of 1.5% solution of Evans blue dye
was injected via the left femoral vein to identify the ischemic
risk area. 2mL of 10% potassium chloride solution was
injected into the femoral vein to stop the heart, and then, the
heart was excised. The presence of Evans blue dye indicated
nonischemic area and its absence indicated area at risk
(AAR). After resecting the right ventricle, the left ventricle
(LV) was cut into ﬁve transverse slices from the apex to the
base. The slices were incubated in 1% triphenyltetrazolium
chloride (TTC) solution at 37◦C for 25min, and they
were then photographed with a digital camera (Cannon,
PowerShot AS1000, Japan) and weighed. For each slice, the
total LV area, the area lacking Evans blue staining (AAR)
and the area lacking TTC staining (infarct area, IA) were
determined using a light electron microscope (Olympus,
Japan). The ratios of IA/AR and AAR/LV were calculated for
each slice and then summed over all slices.
2.5. Detection of Plasma Creatine Kinase (CK) and Lactate
Dehydrogenase (LDH). The cardiac damage was evaluated
by measuring plasma creatine kinase (CK) and lactate
dehydrogenase (LDH). The blood samples were drawn from
the right carotid artery at the end of reperfusion period. The
plasma concentrations of CK and LDH were measured by
automaticbiochemicalanalyzer(AU-2700,Olympus,Japan).Journal of Biomedicine and Biotechnology 3
2.6. Histopathological Examination. At the end of the exper-
iments, the formalin-ﬁxed, paraﬃn-embedded sections of
myocardial tissues were ﬁxed in 10% buﬀered formalin and
sections were prepared from paraﬃn-embedded tissues. The
level of histological tissue injury was assessed by haema-
toxylin and eosin (H&E) staining using light microscopy
(400x magniﬁcation).
2.7. Immunohistochemical Staining for eNOS. The expres-
sion of eNOS was determined by immunohistochemistry.
Paraﬃn-embedded left ventricular tissue blocks were sec-
tioned at 3μm .T h es e c t i o n sw e r ed e p a ra ﬃnized, rehydrated,
t r e a t e dw i t ht a r g e tr e t r i e v a lb u ﬀer, blocked with 3% hydro-
gen peroxide, washed with phosphate-buﬀered saline (PBS),
and blocked with 5% normal goat serum in PBS for 30min.
The sections were then incubated overnight with the poly-
clonal antiendothelial nitric oxide synthase (eNOS) antibody
(rabbit antiendothelial nitric oxide synthase, 1:500, pH 7.2,
with 0.1% bovine serum albumin (Boster Bio-Tech, Wuhan,
China),followedbybiotin-conjugatedsecondaryantibodyat
1:1000 dilutions. Finally, the sections were incubated with
avidin-biotin complex kit (Boster Bio-Tech, Wuhan, China)
and detected by using a diaminobenzidine (DAB) reagent
(Boster Bio-Tech Wuhan, China). The slides were examined
in 400-fold magniﬁcation by light microscopy (Olympus
BX50 Microphotographic System, Japan). For each animal,
three random tissue sections (ﬁve ﬁelds per section) were
examined. Quantitative immunohistochemical assessments
for myocardial eNOS expression were performed as previ-
ously described. A mean optical density (OD), which related
toimmunohistochemicalstainingintensity,wasmeasuredby
image cytometry with HIPAS-2000 image analysis software
(Qianli Technical Imaging, Wuhan China).
2.8.DeterminationofSODandMDA. Themyocardialoxida-
tive stress contents were assayed by the measurement of
SOD and MDA. At the end of reperfusion, the myocardial
supernatant was isolated from ischemia heart tissue samples
by centrifugation at 4000rpm for 10min at 4◦C. The MDA
level in the supernatant was determined by the measurement
ofthethiobarbituricacid(TBA)reactionusingacommercial
kit (Jiancheng Biological, Nanjing, China) [18]. And the
SOD activity in the supernatant was evaluated by inhibition
of nitroblue tetrazolium (NBT) reduction by O
−
2 generated
by the xanthine/xanthine oxidase system using a commercial
kit (Jiancheng Biological, Nanjing, China) [19].
2.9. Assay of NO Production. The level of NO in myocardial
tissue was measured by the Griess method and according
to the indication on the NO assay kit (Jiancheng Biological,
Nanjing,China).Themyocardiumwaslysedandcentrifuged
and then 50μL of Griess reagent was added to 50μLo f
supernatant. Nitrite concentration was determined by a
spectrophotometer (721-100; Tianpu Analytical Instrument
Co., Shanghai, China) at 550nm from a standard curve (0–
100μmol/L) derived from NaNO2.
2.10. Statistical Analysis. Values were expressed as means ±
SEM. All biochemical parameters including plasma LDH,
I/R Rb1 L-NAME
#
∗
I
A
/
A
A
R
(
%
)
0
10
20
30
40
50
60
Rb1 +
L-NAME
Figure 1: Infarct size expressed as percent of the area at risk in
rats subjected to 30min ischemia and 2h of reperfusion. The blue-
stained areas represent nonischemic tissue and red-stained areas
represent the area at risk. Pale areas indicate infarct areas. Results
are expressed as mean ± SEM. n = 6,∗P< 0.01 versus I/R group,
#P< 0.01 versus Rb1 group.
CK, SOD, and MDA were assayed in duplicate. Therefore,
these data are themselves means of duplicate assays. Statis-
tical analysis was performed using SPSS 13.0 for Windows
software. The statistical signiﬁcance was determined by
ANOVA.AvalueofP<0.05wasconsideredtobestatistically
signiﬁcant.
3. Results
3.1. Baseline and Model Characteristics. For each diabetic
animal model, a 4-hour fasting plasma glucose (FPG) was
measured every 14 days. The diabetic rats with fasting
plasma glucose concentrations ≥16.7mmol/L showed signs
of polydipsia, polyphagia and polyuria (Table 1).
3.2. Infarct Size Assessment of the Operated Groups. The ratio
ofareaatriskofleftventricularmass(AAR/LV)didnotdiﬀer
signiﬁcantly among the groups. In I/R group, the infarct size
was 51.7 ± 4.34% of the area at risk (IS/AAR). Pretreatment
with Ginsenoside Rb1 yielded an infarct size of 36.9 ± 2.34%
(P<0.05 versus I/R group). Administration of L-NAME or
I/R + Rb1 + L-NAME did not aﬀect infarct size (P>0.05
versus I/R group). Pretreatment with L-NAME hindered the
cardioprotective eﬀect of Ginsenoside Rb1 preconditioning
(P<0.05 versus Rb1 group) (Figure 1).
3.3. Eﬀects of Ginsenoside Rb1 on Plasma CK and LDH. To
investigate whether Ginsenoside Rb1 limited cardiomyocyte
necrosis, the activity of serum CK and LDH were measured
at the end of reperfusion period. Comparing with Sham
g r o u p ,s e r u mC Ka n dL D Ho fI / Rg r o u pw e r em a r k e d l y4 Journal of Biomedicine and Biotechnology
Table 1: The fasting plasma glucose and body weight of diabetic rats (n = 60).
P a r a m e t e r5 d 2 W4 W6 W8 W
FPG (mmol/L) 19.9 ± 2.4 23.0 ± 2.4 22.9 ± 1.9 22.4 ± 3.8 25.2 ± 2.8
BW (g) 258.5 ± 35.4 273.6 ± 23.2 283.6 ± 28.4 266.0 ± 21.5 242.8 ± 22.3
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Figure 2: Eﬀects of Rb1 with or without L-NAME pretreatment
on plasma levels of CK, LDH after 30min of myocardial ischemia
and 120min of reperfusion. Results are expressed as mean ± SEM.
∗P< 0.01 versus Sham group, #P< 0.01 versus I/R group, ΔP<
0.01 versus Rb1 group.
increased (both P<0.01). After preconditioning with
Ginsenoside Rb1, the CK and LDH levels were signiﬁcantly
lower compared with the I/R group (both P<0.05).
Moreover, pretreatment with L-NAME completely abolished
Ginsenoside Rb1-induced decrease in plasma CK, LDH
(Figure 2).
3.4. Eﬀects of Ginsenoside Rb1 on Myocardial SOD and MDA
Levels. To examine whether Ginsenoside Rb1 decreased the
diabetic myocardial oxidative stress, SOD and MDA levels
in the ischemia heart tissue were measured. Comparing
with Sham group, MDA level in I/R group was markedly
increased, while SOD activity was lower (P<0.05). After
preconditioning with Ginsenoside Rb1, MDA levels in Rb1
and Rb1 + L-NAME groups were decreased signiﬁcantly
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Figure 3: Eﬀect of Ginsenoside Rb1 preconditioning on SOD and
MDA. Results are expressed as mean ± SEM. ∗P< 0.01 versus
Sham group, #P< 0.05 versus I/R group, ΔP< 0.05 versus Rb1
group.
compared with the I/R group, while the activity of SOD were
higher (P<0.05), (Figure 3).
3.5. Eﬀect of Ginsenoside Rb1 on Myocardial NO Production.
To further investigate the biochemical events associated with
Ginsenoside Rb1 pretreatment, NO production in ischemic
heart was evaluated. NO production, which was indicated as
thenitriteformation,wasfoundtobedecreasedinI/Rgroup.
We found that Ginsenoside Rb1 induced a signiﬁcant raise in
nitrite level (P<0.05); however, this eﬀect of elevated nitrite
formation was inhibited with the presence of L-NAME (P<
0.05), (Figure 4).
3.6. Expression of eNOS in the Diabetic Heart. As shown
in Figure 5, a very small amount of eNOS was detected in
myocardial tissue of the Sham group. Signiﬁcantly reduced
expression of eNOS was observed in group I/R (P<0.05,Journal of Biomedicine and Biotechnology 5
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Figure 4: Eﬀect of Ginsenoside Rb1 preconditioning on NO
production.Resultsareexpressedasmean ±SEM. ∗P< 0.05versus
I/R group, #P< 0.01 versus Rb1 group.
versus Sham). When compared with group I/R, group Rb1
had signiﬁcantly higher expression of eNOS (P<0.05).
Pretreatment with L-NAME almost completely abolished the
induction of the expression of eNOS (P<0.05, L-NAME +
Rb1 versus Rb1 group).
3.7. Heart Histopathologic Changes. The histopathological
changes in the ischemic heart tissue at the end of reper-
fusion were assessed by standard H&E staining. As shown
in Figure 6, the myocardium of Sham group maintained
normal tissue structure and shape, and the myocardial ﬁbers
were arranged in an orderly manner. I/R group showed
acute heart injury characterized by areas of necrosis, neu-
trophilic inﬂammation, myocardial, and interstitial edema.
The myocardial ﬁbers were partially ruptured and lysed. Rb1
group revealed markedly reduced neutrophilic inﬂammation
and interstitial edema with preservation of myocardium
compared with I/R group. More importantly, L-NAME was
administeredpriortoRb1,thedestructionofhearttissuewas
more severely as compared with I/R group.
4. Discussion
In this study, Ginsenoside Rb1 preconditioning limited the
heart infarct size and MDA concentrations, while increasing
SODactivityandattenuatingcellulardamage.Theprotective
eﬀects induced by Ginsenoside Rb1 preconditioning were
related to the expression of eNOS and NO. These protective
eﬀects were blocked by an eNOS inhibitor (L-NAME),
suggesting that eNOS activity and endothelium-derived
NO mediated the protective eﬀects of Ginsenoside Rb1
pretreatment.
Severalmechanismshavebeenproposedfortheoxidative
damage during chronic hyperglycemia, such as mitochon-
drial reactive oxygen species (ROS) overproduction [20],
glucose auto-oxidation [21], synthesis of AGEs [22], and
hyperglycemia reduced NO availability. Endothelial dysfunc-
tion has been documented in various forms of diabetes and
even in prediabetic individuals [23, 24]. The pathogenesis
of this endothelial dysfunction involves many components
including increased polyol pathway ﬂux, altered cellular
redox state, increased formation of diacylglycerol, and the
subsequent activation of speciﬁc protein kinase C isoforms,
and accelerated nonenzymatic formation of AGEs. There
are many clinical and experimental evidences suggesting
that increased sympathetic activities, activated cardiac renin-
angiotensinsystem,myocardialischemia/functionalhypoxia,
and elevated circulating levels of glucose result in oxidative
stress in cardiovascular system of diabetic subjects. Oxidative
stress associated with an impaired antioxidant defense status
may play a critical role in subcellular remodeling, calcium-
handling abnormalities, and subsequent diabetic cardiomy-
opathy [25]. A clinical study indicated that systemic oxida-
tive stress occurred during cardiopulmonary bypass and
postcardiopulmonary bypass periods and also in patients
with diabetes mellitus, and the systemic oxidative stress
was higher [26]. So, we hypothesized that Ginsenoside Rb1
pretreatmentmayattenuatemyocardialischemiareperfusion
injurythroughanincreaseintheactivityofeNOS,enhancing
the availability of NO, and decreasing the oxidative stress.
NO released from endothelial cells, is a pivotal vaso-
protective molecule, which maintains normal vascular tone,
regulates leukocyte-endothelial cell interactions, inhibits
platelet aggregation, limits smooth muscle cell prolifera-
tion, and may aﬀect cardiac myocyte function, neutrophil
activation, and free-radical production [11, 27, 28]. Pre-
vious studies clearly demonstrated that the deﬁciency of
eNOS exacerbates myocardial I/R injury [29], and myocar-
dial ischemia and reperfusion are associated with marked
impairment of endothelium-dependent coronary relaxation,
reduced contractility, and cardiac arrhythmias. In many
studies, reperfusion injury has been attributed to a reduced
formation or activity of NO because the NO precursor,
L-arginine, NO donors of diﬀerent chemical structures,
and interventions resulting in stimulated NO production
involvingendothelialreceptorshaveallbeenfoundtoprotect
the heart [30]. Moreover, the overexpression of eNOS, the
administration of NO donors, and inhaled NO gas therapy
all signiﬁcantly protect the myocardium [31]. Yang et al. [32]
also showed that NO released by endothelial NO synthase
(eNOS) is important in blood pressure regulation and also
has an impact on cardiac function and remodeling.
In addition, there are evidences strongly suggesting that
Ginsenoside Rb1 bears various beneﬁcial eﬀects on the
cardiovascular system. In cell culture model, Ginsenoside
Rb1 enhanced NO production and the expression of eNOS
mRNAinTNF-αstimulatedHUVEs.[33].Invitro,Ginseno-
side Rb1 has been shown to reduce homocysteine-induced
endothelialdysfunctionandfreeradicalproductionaswellas
eNOS downregulation in porcine coronary arteries [34–36].
StudyhasshownthatGinsenosideRb1signiﬁcantlyinhibited
cardiocyte apoptosis and reduced ischemia-reperfusion in
rats[15].Recentstudiesdemonstratedthatadministrationof
Ginseng berry signiﬁcantly improved systemic insulin sensi-
tivityandglucosehomeostasisintherats.Othershaveshown
that the Ginsenoside compounds attenuated inhibitory
inﬂammatory response after cardiopulmonary bypass in
patients with congenital heart diseases, which played an6 Journal of Biomedicine and Biotechnology
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Figure 5: Eﬀect of Ginsenoside Rb1 preconditioning on the production of NOx (nitrite and nitrate, metabolites of nitric oxide (NO)).
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Figure 6: Histopathological slides of the diabetic rats heart tissue
(magniﬁcation, ×400).
important role in protecting the heart from ischemic-
reperfusion injury [37]. Additional researches demonstrated
thatGinsenosideplaysasigniﬁcantroleinantihyperglycemic
action [38]. Therefore, it was important to determine
whether pretreatment with Ginsenoside Rb1 would reduce
myocardial infarction after ischemia reperfusion events. In
addition, a previous study showed that Ginsenoside Rb1, a
major active component of Ginseng, could actually induce
NO production and regulate acute eNOS activation in
human aortic endothelial cells [39].
Inthisstudy,byusinganinvivoratmodel,wefoundthat
Ginsenoside Rb1 preconditioning signiﬁcantly decreased
infarct size and plasma CK, LDH after 30min of regional
myocardial ischemia and 120min of reperfusion, and Gin-
senoside Rb1 pretreatment attenuated the increase in necro-
sis, neutrophilic inﬂammation respond, and myocardial and
interstitial edema. The myocardial MDA level, reﬂecting the
lipid peroxide and oxidative stress, was also signiﬁcantly
suppressed in Rb1 group, while the SOD activity was
increased. Ginsenoside Rb1 upregulated eNOS and NO
contents, while eNOS inhibitor (L-NAME) reversed the pro-
tective eﬀect of Ginsenoside Rb1 pretreatment. Therefore,
our study demonstrated the protective eﬀect of Ginsenoside
Rb1 pretreatment, at least in part, by eNOS and NO. Certain
limitationsofthepresentstudyneedtobenoted.Thecurrent
study did not investigate mRNA and protein expressions of
eNOS. This will be the goal of future study.Journal of Biomedicine and Biotechnology 7
In summary, our study suggests that Ginsenoside Rb1
preconditioning attenuated the severity of heart injury
induced by myocardial ischemia/reperfusion injury in dia-
betic rats. The protective eﬀect of Ginsenoside Rb1 precon-
ditioning was mediated in part through the induction of
endogenous NO released by eNOS.
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